首页> 外文期刊>Neuro-Oncology >Cognitive and brain structural changes in long-term oligodendroglial tumor survivors
【24h】

Cognitive and brain structural changes in long-term oligodendroglial tumor survivors

机译:长期少突胶质肿瘤幸存者的认知和脑结构变化

获取原文
获取原文并翻译 | 示例
           

摘要

Background. We identify cognitive impairment and MRI structural brain changes in long-term oligodendroglial tumor survivors treated with radiation therapy (RT) alone (21%) or with chemotherapy (CT) (79%).Methods. Oligodendroglial tumor patients (based on the World Health Organization [WHO] 2007 classification) who completed RT +/- CT at least 2 years before the study initiation, were classified into 3 groups according to the time treatment was completed: Group 1 = 2-5 years (n = 22), Group 2 = 6-10 years (n = 13), and Group 3 >10 years (n = 13). All patients had a cross-sectional neuropsychological evaluation (n = 48) and a longitudinal volumetric analysis (gray matter [GM; n = 34]) between postsurgical and last follow-up MRI. White matter (WM) changes on MRI were assessed using a qualitative scale.Results. There were no differences regarding tumor or treatment-related characteristics between groups. Six of 22 patients (27.3%) in Group 1; 5/13 (38.5%) in Group 2; and 9/13 (69.2%) in Group 3 had cognitive impairment that was considered severe in 3/22 patients (13.6%) in Group 1; 4/13 (30.8%) in Group 2; and 6/13 (46.2%) in Group 3. Patients in Groups 2 and 3 showed significant GM atrophy and more leukoencephalopathy than Group 1. Cognitive deficits were associated with brain atrophy and WM changes.Conclusions. Long-term oligodendroglial tumor survivors who underwent standard RT +/- CT treatment, mainly >5 years of its completion, present cognitive impairment, especially on memory and executive functions, associated with late GM and WM damage, thus highlighting the need of developing future strategies in patients with oligodendroglial tumor and long expected survival.
机译:背景。我们确定了仅接受放射治疗(RT)(21%)或接受化疗(CT)(79%)治疗的长期少突胶质肿瘤幸存者的认知障碍和MRI结构性脑变化。在研究开始至少两年前完成RT +/- CT的少突胶质细胞瘤患者(基于世界卫生组织[WHO] 2007分类),根据治疗完成时间分为三组:第1组= 2- 5年(n = 22),组2 = 6-10年(n = 13)和组3> 10年(n = 13)。所有患者在术后和最后一次MRI检查之间进行横断面神经心理学评估(n = 48)和纵向容量分析(灰质[GM; n = 34])。使用定性量表评估MRI上的白质(WM)变化。两组之间在肿瘤或治疗相关特征方面没有差异。第一组的22名患者中有6名(27.3%);第2组5/13(38.5%);第三组中有9/13(69.2%)的认知障碍在第一组中有3/22患者(13.6%)被认为是严重的;第2组的4/13(30.8%);和6/13(46.2%)在第3组中。与第1组相比,第2和3组中的患者表现出明显的GM萎缩和白质脑病。认知缺陷与脑萎缩和WM改变有关。长期接受标准RT +/- CT治疗的少突胶质细胞瘤幸存者(主要是完成时间> 5年)表现出认知障碍,尤其是记忆和执行功能方面的障碍,与晚期GM和WM损伤相关,因此突出了发展未来的需要少突胶质细胞瘤和预期生存期长的患者的治疗策略。

著录项

  • 来源
    《Neuro-Oncology》 |2019年第11期|1470-1479|共10页
  • 作者单位

    Bellvitge Univ Hosp Bellvitge Biomed Res Inst Catalan Inst Oncol IDIBELL Neurooncol Unit Oncobell Program Barcelona Spain;

    CES Univ Colombian Neurol Inst Neurooncol Unit Medellin Colombia;

    IDIBELL Cognit & Brain Plast Grp Barcelona Spain;

    Hosp Clin Barcelona August Pi & Sunyer Biomed Res Inst IDIBAPS Dept Neurol Barcelona Spain;

    Bellvitge Univ Hosp Bellvitge Biomed Res Inst Catalan Inst Oncol IDIBELL Neurooncol Unit Oncobell Program Barcelona Spain|Autonomous Univ Barcelona Dept Cell Biol Physiol & Immunol Inst Neurosci Biomed Res Networking Ctr Neurodegenerat Dis CIBE Bellaterra Spain;

    Bellvitge Univ Hosp Bellvitge Biomed Res Inst Catalan Inst Oncol IDIBELL Neurooncol Unit Oncobell Program Barcelona Spain|IDIBELL Cognit & Brain Plast Grp Barcelona Spain;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    cognition; long-term survivors; neurotoxicity; oligodendroglioma; radiotherapy;

    机译:认识;长期幸存者;神经毒性少突胶质细胞瘤放射疗法;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号